Medicinal perspectives and Structure-activity relationship studies of Pyrimidine based Bruton’s tyrosine kinase inhibitors as potential anticancer agents

[1]  Hongmei Wu,et al.  Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects. , 2022, European journal of medicinal chemistry.

[2]  D. Bandyopadhyay,et al.  Design, synthesis and biological evaluation of novel pyrazolo-pyrimidin-amines as potent and selective BTK inhibitors. , 2022, Bioorganic chemistry.

[3]  Zhuo Yang,et al.  Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors. , 2022, European journal of medicinal chemistry.

[4]  Shan-Liang Sun,et al.  Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance. , 2022, Journal of medicinal chemistry.

[5]  Chi-Hoon Park,et al.  Pyrazolo[3,4‐ d ]pyrimidine derivatives as irreversible Bruton's tyrosine kinase inhibitors , 2022, Bulletin of the Korean Chemical Society.

[6]  J. Hsieh,et al.  Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors , 2021, Journal of enzyme inhibition and medicinal chemistry.

[7]  M. Sawa,et al.  Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase. , 2021, Journal of medicinal chemistry.

[8]  Yang Liu,et al.  Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma. , 2021, Bioorganic chemistry.

[9]  Huijun Sun,et al.  Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML. , 2020, Bioorganic chemistry.

[10]  S. Sheikh,et al.  Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. , 2020, Journal of medicinal chemistry.

[11]  D. Murrell,et al.  Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceus. , 2020, Veterinary dermatology.

[12]  Xiaodong Ma,et al.  JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma. , 2019, Bioorganic chemistry.

[13]  W. Shi,et al.  Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors. , 2019, Bioorganic & medicinal chemistry.

[14]  Bo Sun,et al.  Novel Pyrimidines as Multitarget Protein Tyrosine Kinase Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) , 2019, ChemMedChem.

[15]  M. Kool,et al.  Enhanced Bruton’s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis , 2019, Respiratory Research.

[16]  Yuxin Yin,et al.  Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. , 2019, Bioorganic & medicinal chemistry.

[17]  Yang Liu,et al.  Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL. , 2019, Bioorganic chemistry.

[18]  Honglin Li,et al.  Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors. , 2019, Bioorganic & medicinal chemistry.

[19]  Mingli Xiang,et al.  Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis. , 2019, European journal of medicinal chemistry.

[20]  Q. You,et al.  Design, synthesis and biological evaluation of novel 2-phenyl pyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors. , 2019, MedChemComm.

[21]  Yingxia Li,et al.  Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors. , 2019, Bioorganic & medicinal chemistry letters.

[22]  A. Follis,et al.  Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk. , 2018, Bioorganic & medicinal chemistry letters.

[23]  Huijun Sun,et al.  Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines. , 2018, Bioorganic & medicinal chemistry.

[24]  Yingxia Li,et al.  Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors. , 2018, Bioorganic & medicinal chemistry.

[25]  Qingsong Liu,et al.  Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors. , 2018, Journal of medicinal chemistry.

[26]  M. Sawa,et al.  Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors. , 2018, Bioorganic & medicinal chemistry letters.

[27]  W. Wierda.  Managing BTK Inhibitor-Refractory CLL , 2017 .

[28]  R. Hendriks,et al.  BTK Signaling in B Cell Differentiation and Autoimmunity. , 2015, Current topics in microbiology and immunology.

[29]  Laurens P. Kil,et al.  Targeting Bruton's tyrosine kinase in B cell malignancies , 2014, Nature Reviews Cancer.

[30]  O. Witte,et al.  Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer , 2014, Molecular and Cellular Biology.

[31]  Shuqiang Li,et al.  Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition , 2016, Nature Communications.

[32]  Yamei Chen,et al.  Ibrutinib and novel BTK inhibitors in clinical development , 2013, Journal of Hematology & Oncology.

[33]  Michael L. Wang,et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.

[34]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[35]  J. Buggy,et al.  Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy , 2012, International reviews of immunology.

[36]  A. Kuglstatter,et al.  Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. , 2012, Journal of medicinal chemistry.

[37]  F. Uckun,et al.  Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity , 2010, Expert opinion on therapeutic patents.

[38]  L. Silvian,et al.  Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases , 2010, Protein science : a publication of the Protein Society.

[39]  Mauno Vihinen,et al.  Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain , 2009, Immunological reviews.

[40]  T. Kurosaki,et al.  Tyrosine kinases and their substrates in B lymphocytes , 2009, Immunological reviews.

[41]  M. Simonetta,et al.  Physical and functional characterization of the genetic locus of IBtk, an inhibitor of Bruton's tyrosine kinase: evidence for three protein isoforms of IBtk , 2008, Nucleic acids research.

[42]  M. Vihinen,et al.  BTKbase: the mutation database for X‐linked agammaglobulinemia , 2006, Human mutation.

[43]  O. Sanal,et al.  A novel mutation leading to a deletion in the SH3 domain of Bruton's tyrosine kinase. , 2006, The Turkish journal of pediatrics.

[44]  J. Graves,et al.  How the gene content of human sex chromosomes evolved. , 2006, Current opinion in genetics & development.

[45]  J. Kehrl,et al.  Roles for phosphoinositide 3‐kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing , 2006, European journal of immunology.

[46]  V. Ta,et al.  Bruton’s Tyrosine Kinase and SLP-65 Regulate Pre-B Cell Differentiation and the Induction of Ig Light Chain Gene Rearrangement1 , 2006, The Journal of Immunology.

[47]  C. Jefferies,et al.  MyD88 Adapter-like (Mal) Is Phosphorylated by Bruton's Tyrosine Kinase during TLR2 and TLR4 Signal Transduction* , 2006, Journal of Biological Chemistry.

[48]  J. Rowley,et al.  Mimicry of a constitutively active pre–B cell receptor in acute lymphoblastic leukemia cells , 2005, The Journal of experimental medicine.

[49]  A. Rolink,et al.  Transcriptional networks in developing and mature B cells , 2005, Nature Reviews Immunology.

[50]  G. Cheetham.  Novel protein kinases and molecular mechanisms of autoinhibition. , 2004, Current opinion in structural biology.

[51]  N Srinivasan,et al.  Structural modes of stabilization of permissive phosphorylation sites in protein kinases: distinct strategies in Ser/Thr and Tyr kinases. , 2004, Journal of molecular biology.

[52]  Uckun Fm,et al.  Therapeutic potential of inhibiting Bruton's tyrosine kinase, (BTK). , 2004 .

[53]  C. Jefferies,et al.  Bruton's tyrosine kinase (Btk)-the critical tyrosine kinase in LPS signalling? , 2004, Immunology letters.

[54]  R. Hendriks,et al.  Function of Bruton’s Tyrosine Kinase during B Cell Development Is Partially Independent of Its Catalytic Activity 1 , 2003, The Journal of Immunology.

[55]  J. Monroe,et al.  Transitional B cells: step by step towards immune competence. , 2003, Trends in immunology.

[56]  Maria Deak,et al.  High-Resolution Structure of the Pleckstrin Homology Domain of Protein Kinase B/Akt Bound to Phosphatidylinositol (3,4,5)-Trisphosphate , 2002, Current Biology.

[57]  D. Kövesdi,et al.  BCR mediated signal transduction in immature and mature B cells. , 2002, Immunology letters.

[58]  L. Berg,et al.  New insights into the regulation and functions of Tec family tyrosine kinases in the immune system. , 2002, Current opinion in immunology.

[59]  G. Scapin.  Structural biology in drug design: selective protein kinase inhibitors. , 2002, Drug discovery today.

[60]  R. Hendriks,et al.  Impaired Precursor B Cell Differentiation in Bruton’s Tyrosine Kinase-Deficient Mice1 , 2002, The Journal of Immunology.

[61]  C. I. Smith,et al.  Functional Interaction of Caveolin-1 with Bruton's Tyrosine Kinase and Bmx* , 2002, The Journal of Biological Chemistry.

[62]  S. Rath,et al.  Macrophage Effector Functions Controlled by Bruton’s Tyrosine Kinase Are More Crucial Than the Cytokine Balance of T Cell Responses for Microfilarial Clearance 1 , 2002, The Journal of Immunology.

[63]  Amber C. Donahue,et al.  Phosphoinositide 3-kinase and Bruton's tyrosine kinase regulate overlapping sets of genes in B lymphocytes , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[64]  G. Thomas,et al.  Differences in telomere length between homologous chromosomes in humans. , 2001, Nucleic acids research.

[65]  O. Witte,et al.  Bruton's tyrosine kinase is required for signaling the CD79b-mediated pro-B to pre-B cell transition. , 2001, International immunology.

[66]  B. Christensson,et al.  Nucleocytoplasmic Shuttling of Bruton's Tyrosine Kinase* , 2000, The Journal of Biological Chemistry.

[67]  C. Webb,et al.  The Transcription Factor Bright Associates with Bruton’s Tyrosine Kinase, the Defective Protein in Immunodeficiency Disease1 , 2000, The Journal of Immunology.

[68]  M. Vihinen,et al.  Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA). , 2000, Frontiers in bioscience : a journal and virtual library.

[69]  Mary Ellen Conley,et al.  X-linked agammaglobulinemia , 2000, Clinical reviews in allergy & immunology.

[70]  A. Satterthwaite,et al.  The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. , 2000, Immunological reviews.

[71]  A. Rolink,et al.  Repertoire selection by pre‐B‐cell receptors and B‐cell receptors, and genetic control of B‐cell development from immature to mature B cells , 2000, Immunological reviews.

[72]  R. Sen,et al.  Bruton's Tyrosine Kinase Links the B Cell Receptor to Nuclear Factor κb Activation , 2000, The Journal of experimental medicine.

[73]  W. Khan,et al.  Bruton's Tyrosine Kinase Is Required for Activation of Iκb Kinase and Nuclear Factor κb in Response to B Cell Receptor Engagement , 2000, The Journal of experimental medicine.

[74]  I. Weissman,et al.  Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[75]  C. I. Smith,et al.  Redistribution of Bruton's tyrosine kinase by activation of phosphatidylinositol 3‐kinase and Rho‐family GTPases , 2000, European journal of immunology.

[76]  D. Nemazee,et al.  Distinct Signal Thresholds for the Unique Antigen Receptor–Linked Gene Expression Programs in Mature and Immature B Cells , 1999, The Journal of experimental medicine.

[77]  H. Mano.  Tec family of protein-tyrosine kinases: an overview of their structure and function. , 1999, Cytokine & growth factor reviews.

[78]  A. Rolink,et al.  Characterization of immature B cells by a novel monoclonal antibody, by turnover and by mitogen reactivity , 1998, European journal of immunology.

[79]  S. Watson,et al.  A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen , 1998, Current Biology.

[80]  H. Ochs,et al.  Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B‐cell receptor activation , 1998, The EMBO journal.

[81]  L. Alvesalo.  Sex chromosomes and human growth , 1997, Human Genetics.

[82]  H. Ochs,et al.  X-linked agammaglobulinemia. A clinical and molecular analysis. , 1996, Medicine.

[83]  D J Rawlings,et al.  Regulation of Btk function by a major autophosphorylation site within the SH3 domain. , 1996, Immunity.

[84]  J. Kinet,et al.  Activation of BTK by a Phosphorylation Mechanism Initiated by SRC Family Kinases , 1996, Science.

[85]  K. Isselbacher,et al.  Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[86]  R. Nelson,et al.  Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[87]  D J Rawlings,et al.  Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. , 1993, Science.

[88]  E. Timmers,et al.  X-linked agammaglobulinemia. , 1991, Clinical immunology and immunopathology.

[89]  Irving S. Sigal,et al.  Cloning of bovine GAP and its interaction with oncogenic ras p21 , 1988, Nature.

[90]  G L Ada,et al.  The clonal-selection theory. , 1987, Scientific American.

[91]  H. Grey,et al.  Antigen recognition by H-2-restricted T cells. I. Cell-free antigen processing , 1983, The Journal of experimental medicine.

[92]  I. Weissman,et al.  A cell-surface molecule involved in organ-specific homing of lymphocytes , 1983, Nature.

[93]  A. I. Spriggs,et al.  Chromosomes of Human Cancer Cells , 1962, British medical journal.

[94]  Yang Liu,et al.  Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma. , 2019, Bioorganic chemistry.

[95]  Brandon J. Bravo,et al.  Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. , 2011, Nature chemical biology.

[96]  O. Witte,et al.  Mutational analysis of the SH2-kinase linker region of Bruton's tyrosine kinase defines alternative modes of regulation for cytoplasmic tyrosine kinase families. , 2006, International immunology.

[97]  A. Tarakhovsky,et al.  Protein Kinase C (cid:2) Controls Nuclear Factor (cid:3) B Activation in B Cells Through Selective Regulation of the I (cid:3) B Kinase (cid:4) , 2002 .

[98]  R. Hendriks,et al.  Role of Bruton's Tyrosine Kinase in B Cell Development , 2001, Developmental immunology.

[99]  W. Paul,et al.  Regulation of B-cell growth and differentiation by soluble factors. , 1983, Annual review of immunology.